U6Z.F
Uranium Energy Corp.
FrankfurtEUREQUITY
Energy
DELAYED
Last price
10.92
■ 0.00 (0.00%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
10.92
Day high
10.92
Day low
9.52
Volume
1.53K
Market cap
$5.40B
P/E (TTM)
—
52W range
7.80 – 17.25
Trailing performance
Returnvs SPY
1W
+11.31%
+12.7%
1M
+27.42%
+23.7%
3M
-6.67%
-9.8%
6M
-18.87%
-29.9%
YTD
+4.92%
-7.4%
1Y
+22.02%
+2.0%
3Y
+174.37%
+100.2%
5Y
+295.65%
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on U6Z.F open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
9.18M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 31, 26 | ADNANI AMIR Chief Executive Officer |
STOCK | 185.00K | $0 | Indirect |
| Jul 31, 26 | MELBYE SCOTT ERIC Officer |
— | 133.30K | — | Direct |
| Jul 31, 26 | BERG BRENT Officer |
— | 10.39K | — | Direct |
| Jul 31, 26 | MAN JOSEPHINE Chief Financial Officer |
— | 16.10K | — | Direct |
| Jul 31, 26 | ADNANI AMIR Chief Executive Officer |
— | 796.83K | — | Direct |
| Jul 31, 26 | ABRAHAM EDWARD SPENCER Director |
— | 26.80K | — | Direct |
| Jul 31, 26 | DELLA VOLPE VINCENT Director |
— | 10.74K | — | Direct |
| Jul 31, 26 | KONG DAVID Director |
— | 10.74K | — | Direct |
| Jul 31, 26 | CANTY TRECIA M Director |
— | 10.74K | — | Direct |
| Jul 31, 26 | BALLESTA MOYA GLORIA L Director |
— | 10.74K | — | Direct |
| Nov 20, 25 | MELBYE SCOTT ERIC Officer |
CONVERSION | 125.00K | $117.76K | Direct |
| Oct 1, 25 | MAN JOSEPHINE Chief Financial Officer |
— | 5.37K | — | Direct |
| Aug 6, 25 | KONG DAVID Director |
SELL | 50.80K | $488.69K | Direct |
| Aug 6, 25 | KONG DAVID Director |
CONVERSION | 75.00K | $68.25K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ABRAHAM EDWARD SPENCER |
Director | 732.66K | Conversion of Exercise of derivative security |
ADNANI AMIR |
Chief Executive Officer | — | Stock Gift |
BALLESTA MOYA GLORIA L |
Director | 113.63K | Conversion of Exercise of derivative security |
BERG BRENT |
Officer | 11.86K | Conversion of Exercise of derivative security |
CANTY TRECIA M |
Director | 24.34K | Conversion of Exercise of derivative security |
DELLA VOLPE VINCENT |
Director | 217.97K | Conversion of Exercise of derivative security |
KONG DAVID |
Director | 187.23K | Conversion of Exercise of derivative security |
MAN JOSEPHINE |
Chief Financial Officer | 48.81K | Conversion of Exercise of derivative security |
MELBYE SCOTT ERIC |
Officer | 1.24M | Conversion of Exercise of derivative security |
Fundamentals
Market cap$5.40B
Enterprise value$4.92B
Revenue (TTM)$20.20M
Gross profit$-80.00M
EBITDA$-120.76M
Net income$-103.67M
EPS (TTM)$-0.19
Free cash flow$-82.07M
Total cash$488.05M
Total debt$1.91M
Book value / share$2.52
Shares outstanding494.87M
Float485.74M
Short % of float—
Dividend yield—
Beta (5Y)1.21
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book4.33
EV / revenue243.46
EV / EBITDA-40.72
Gross margin0.00%
Operating margin-629.66%
Profit margin0.00%
Return on equity-8.96%
Return on assets-6.25%
Debt / equity0.14
Current ratio32.67
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $66.84M | $224.00K | $164.39M | $23.16M | +29,737.9% |
| Operating revenue | $66.84M | $224.00K | $164.39M | $23.16M | +29,737.9% |
| Cost of revenue | $42.36M | $187.00K | $114.72M | $15.87M | +22,552.4% |
| Gross profit | $24.48M | $37.00K | $49.67M | $7.29M | +66,054.1% |
| Selling, general & admin | $27.36M | $22.02M | $19.99M | $14.71M | +24.2% |
| Total operating expense | $97.90M | $56.59M | $40.62M | $26.24M | +73.0% |
| Operating income | -$73.42M | -$56.55M | $9.05M | -$18.95M | -29.8% |
| Net interest income | $2.58M | $1.80M | -$455.00K | -$1.42M | +43.0% |
| Pre-tax income | -$90.44M | -$34.26M | -$2.44M | $5.25M | -164.0% |
| Tax provision | -$2.78M | -$5.03M | $870.00K | -$5.00K | +44.8% |
| Net income | -$87.66M | -$29.22M | -$3.31M | $5.25M | -200.0% |
| Net income to common | -$87.66M | -$29.22M | -$3.31M | $5.25M | -200.0% |
| Basic EPS | -0.20 | -0.07 | -0.01 | 0.02 | -185.7% |
| Diluted EPS | -0.20 | -0.07 | -0.01 | 0.02 | -185.7% |
| EBIT | -$88.99M | -$33.43M | -$1.63M | $6.77M | -166.2% |
| EBITDA | -$84.50M | -$31.25M | $375.00K | $8.14M | -170.5% |
| Basic shares | 427.68M | 397.31M | 364.79M | 271.02M | +7.6% |
| Diluted shares | 427.68M | 397.31M | 364.79M | 280.10M | +7.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $148.93M | $87.53M | $45.61M | $32.54M | +70.1% |
| Cash & short-term investments | $148.93M | $156.26M | $45.61M | $32.54M | -4.7% |
| Inventory | $79.28M | $75.83M | $6.21M | $66.57M | +4.5% |
| Total current assets | $234.02M | $235.24M | $55.20M | $102.19M | -0.5% |
| Property, plant & equipment | $777.16M | $578.05M | $585.29M | $202.18M | +34.4% |
| Total assets | $1.11B | $889.83M | $737.59M | $354.25M | +24.5% |
| Total current liabilities | $26.43M | $29.22M | $12.19M | $8.50M | -9.5% |
| Total liabilities | $123.75M | $111.72M | $105.76M | $27.34M | +10.8% |
| Retained earnings | -$406.56M | -$318.90M | -$289.68M | -$286.37M | -27.5% |
| Shareholder equity | $983.90M | $778.11M | $631.83M | $326.91M | +26.4% |
| Working capital | $207.58M | $206.02M | $43.01M | $93.69M | +0.8% |
| Net tangible assets | $983.90M | $778.11M | $631.83M | $326.91M | +26.4% |
| Shares issued | 454.02M | 410.36M | 378.45M | 289.64M | +10.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$87.66M | -$29.22M | -$3.31M | $5.25M | -200.0% |
| Depreciation & amortisation | $4.49M | $2.18M | $2.01M | $1.38M | +105.5% |
| Stock-based compensation | $6.01M | $5.17M | $5.52M | $4.68M | +16.3% |
| Change in working capital | -$4.32M | -$59.32M | $57.03M | -$35.49M | +92.7% |
| Operating cash flow | -$64.46M | -$106.49M | $72.57M | -$52.99M | +39.5% |
| Capital expenditure | -$5.70M | -$3.43M | -$656.00K | -$1.21M | -66.1% |
| Investing cash flow | -$157.03M | -$24.64M | -$124.78M | -$110.84M | -537.3% |
| Share buybacks | — | — | — | -$557.00K | — |
| Financing cash flow | $284.84M | $173.08M | $65.42M | $157.27M | +64.6% |
| Free cash flow | -$70.15M | -$109.92M | $71.92M | -$54.20M | +36.2% |
| End cash position | $158.14M | $94.78M | $52.87M | $39.79M | +66.8% |
| Line item | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 | 2025-01-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $20.20M | $0 | $0 | $0 | — | -100.0% |
| Operating revenue | $0 | $20.20M | $0 | $0 | $0 | — | -100.0% |
| Cost of revenue | $0 | $10.17M | $0 | $0 | $0 | — | -100.0% |
| Gross profit | $0 | $10.03M | $0 | $0 | $0 | — | -100.0% |
| Selling, general & admin | $9.39M | $8.09M | $7.67M | $8.90M | $6.13M | — | +16.1% |
| Total operating expense | $40.75M | $33.48M | $30.07M | $32.95M | $23.21M | — | +21.7% |
| Operating income | -$40.75M | -$23.45M | -$30.07M | -$32.95M | -$23.21M | — | -73.8% |
| Net interest income | $3.82M | $3.40M | $2.04M | $713.00K | $167.00K | — | +12.2% |
| Pre-tax income | -$52.94M | -$13.93M | -$11.01M | -$27.50M | -$29.78M | — | -280.0% |
| Tax provision | -$596.00K | $6.00K | -$668.00K | -$447.00K | $434.00K | — | -10,033.3% |
| Net income | -$52.34M | -$13.94M | -$10.34M | -$27.05M | -$30.21M | — | -275.6% |
| Net income to common | -$52.34M | -$13.94M | -$10.34M | -$27.05M | -$30.21M | — | -275.6% |
| Basic EPS | -0.11 | -0.03 | -0.02 | — | -0.07 | -0.02 | -266.7% |
| Diluted EPS | -0.11 | -0.03 | -0.02 | — | -0.07 | -0.02 | -266.7% |
| EBIT | -$52.54M | -$13.43M | -$10.29M | -$27.09M | -$29.37M | — | -291.2% |
| EBITDA | -$50.72M | -$11.73M | -$8.81M | -$25.66M | -$27.97M | — | -332.6% |
| Basic shares | 490.70M | 484.09M | 467.94M | — | 429.94M | 423.20M | +1.4% |
| Diluted shares | 490.70M | 484.09M | 467.94M | — | 429.94M | 423.20M | +1.4% |
| Line item | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $488.05M | $486.35M | $454.72M | $148.93M | $71.40M | +0.4% |
| Cash & short-term investments | $488.05M | $486.35M | $454.72M | $148.93M | $71.40M | +0.4% |
| Accounts receivable | — | $20.20M | — | — | — | — |
| Inventory | $86.45M | $84.69M | $81.66M | $79.28M | $76.36M | +2.1% |
| Total current assets | $581.63M | $597.65M | $543.01M | $234.02M | $152.66M | -2.7% |
| Property, plant & equipment | $782.42M | $781.24M | $774.87M | $777.16M | $777.89M | +0.2% |
| Total assets | $1.54B | $1.53B | $1.43B | $1.11B | $1.01B | +0.4% |
| Total current liabilities | $17.80M | $20.81M | $19.59M | $26.43M | $15.10M | -14.4% |
| Total liabilities | $116.58M | $119.69M | $116.03M | $123.75M | $115.02M | -2.6% |
| Retained earnings | -$483.18M | -$430.83M | -$416.90M | -$406.56M | -$379.50M | -12.1% |
| Shareholder equity | $1.42B | $1.41B | $1.31B | $983.90M | $892.79M | +0.6% |
| Working capital | $563.83M | $576.85M | $523.42M | $207.58M | $137.57M | -2.3% |
| Net tangible assets | $1.42B | $1.41B | $1.31B | $983.90M | $892.79M | +0.6% |
| Shares issued | 493.32M | 489.27M | 483.21M | 454.02M | 435.03M | +0.8% |
| Line item | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$52.34M | -$13.94M | -$10.34M | -$27.05M | -$30.21M | -275.6% |
| Depreciation & amortisation | $1.81M | $1.71M | $1.48M | $1.43M | $1.41M | +6.5% |
| Stock-based compensation | $2.22M | $2.14M | $1.68M | $1.30M | $1.34M | +3.5% |
| Change in working capital | $15.30M | -$21.82M | -$9.70M | $6.10M | -$228.00K | +170.1% |
| Operating cash flow | -$17.63M | -$38.12M | -$34.31M | -$23.46M | -$20.74M | +53.8% |
| Capital expenditure | -$3.63M | -$941.00K | -$1.13M | -$1.02M | -$2.13M | -285.4% |
| Investing cash flow | -$45.79M | -$36.35M | -$1.13M | -$18.46M | -$2.13M | -26.0% |
| Financing cash flow | $59.34M | $106.09M | $339.68M | $119.45M | $32.74M | -44.1% |
| Free cash flow | -$21.25M | -$39.06M | -$35.44M | -$24.48M | -$22.87M | +45.6% |
| End cash position | $489.93M | $494.00M | $462.38M | $158.14M | $80.60M | -0.8% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $9.00M | 0.0% |
| Next quarter | — | — | $5.00M | 0.0% |
| Current year | — | — | $25.17M | -62.4% |
| Next year | — | — | $125.26M | +397.7% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders1.86%
Held by institutions88.44%
Institutions holding566
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
9.80
+11.42% from price
SMA 20
9.25
+18.02% from price
SMA 50
9.23
+18.33% from price
SMA 100
10.55
+3.46% from price
SMA 200
11.40
-4.22% from price
EMA 12
9.68
+12.80% from price
EMA 26
9.41
+16.03% from price
EMA 50
9.57
+14.10% from price
RSI (14)
68.3
Neutral
MACD (12,26,9)
0.27
Hist 0.13
ATR (14)
0.39
3.61% of price
Realised vol 30D
66.3%
Annualised
Bollinger upper
10.78
20, 2σ
Bollinger lower
7.73
20, 2σ
50 / 200 cross
Death
9.23 vs 11.40
Trend bias
Below 200
-4.22%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.44
Less volatile than market
Correlation to SPY
0.07
Largely independent
Realised vol 30D
66.3%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-53.8%
Peak to trough
Max drawdown 5Y
-63.1%
Peak to trough
ATR 14
0.39
3.61% of price
Beta (reported)
1.21
5Y monthly, from filing
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 10, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 20, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 11, 26 | TD Securities | MAINTAINED | Buy | Buy |
| Mar 11, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Dec 11, 25 | Roth Capital | MAINTAINED | Buy | Buy |
| Sep 26, 25 | Goldman Sachs | MAINTAINED | Buy | Buy |
| Sep 25, 25 | Roth Capital | MAINTAINED | Buy | Buy |
| Sep 25, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 25, 25 | BMO Capital | DOWNGRADE | Outperform | Market Perform |
| Sep 3, 25 | Roth Capital | MAINTAINED | Buy | Buy |
| Aug 6, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 3, 25 | BMO Capital | INITIATED | — | Outperform |
Headlines
Oleria and Happiest Minds Partner to Accelerate Modern Identity Governance for AI-First Enterprises
ACCESS Newswire · 6m ago
Vicore Pharma to Present at the European Respiratory Society Congress 2026
ACCESS Newswire · 6m ago
Dollar trading near multi-month lows, restrained by debt nerves
Reuters · 6m ago
Billionaire Investor Stanley Druckenmiller Sold Broadcom, Intel, and Micron and Bought Another Chip Stock That Expects to Double Data Center Sales in 2027
Motley Fool · 16m ago
TME Pharma provides update on its activities
GlobeNewswire · 16m ago
American Chemical Society Names Syngenta's Camilla Corsi the 2026 Winner of Prestigious International Award for Research in Agrochemicals
Business Wire · 21m ago
Valerio Therapeutics Announces Signing of Definitive Agreements for the Acquisition of Etherna Immunotherapies, Building a Leading Platform in Targeted RNA, and €40.25 Million PIPE Financing From New and Existing Investors
Business Wire · 21m ago
Board Update
GlobeNewswire · 21m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.